OncoMatch

OncoMatch/Clinical Trials/NCT06525571

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Is NCT06525571 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Cysview and Karl Storz D-Light C Photodynamic Diagnostic (PDD) system for bladder cancer.

Phase 3RecruitingJohns Hopkins UniversityNCT06525571Data as of Jun 2026

Treatment: Cysview · Karl Storz D-Light C Photodynamic Diagnostic (PDD) systemComparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

CysviewKarl Storz D-Light C Photodynamic Diagnostic (PDD) system

Cancer type

Urothelial Carcinoma

Disease stage

Excluded: Stage MUSCLE-INVASIVE BLADDER CANCER

high-risk non-muscle invasive bladder cancer

Prior therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Sibley Memorial Hospital · Washington D.C., District of Columbia
  • Johns Hopkins University School of Medicine · Baltimore, Maryland

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06525571 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior radiation therapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify